Exclusive Summary

• Possesses highly scarce EU-EMA and US-FDA dual GMP certifications, seamlessly clearing regulatory and market access hurdles for any highly regulated market globally.
• As the next-generation 'Best-in-Class' triple agonist, securing our distribution rights early empowers overseas clients to snatch first-to-file generic advantages and capture underserved non-patent markets.
• Backed by China's scalable advanced peptide manufacturing capacities, we drastically reduce costs while maintaining top-tier Western quality standards, directly empowering clients to harvest the forecasted $100 billion obesity and diabetes blue-ocean market.